Conditions: Hyperhidrosis
Keywords: Neuromuscular Agents Botulinum Toxin Type A Sweating Sweat Gland Disease Axillary Hyperhidrosis Skin Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 152
Healthy volunteers: no

Brief summary:
The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in total for each patient) as intradermal injections based on gravimetric assessment (measurement of spontaneous axillary sweat production) for axillary hyperhidrosis.

Detailed description:

Arms:
arm 1: Onabotulinum toxin type A arm 2: Placebo

Interventions: intervention 1: GSK1358820 intervention 2: Placebo
Intervention descriptions: intervention 1: Onabotulinum toxin type A intervention 2: Placebo

Protocol document: